search
Back to results

Comparison of Mg Vs. K Supplementation on Insomnia in Diabetics

Primary Purpose

Focus of Study is on Insomnia Among Diabetic Patients

Status
Unknown status
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
Magnesium and/ or Potassium
Sponsored by
University of Lahore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Focus of Study is on Insomnia Among Diabetic Patients focused on measuring Insomnia, Diabetes Mellitus, Magnesium, Potassium, Melatonin, Cortisol, Insulin resistance, Quality of Life

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Patients of diabetes mellitus with insomnia

    • Adult diabetic patients aged between 19 to 65 years
    • Patients of both genders
    • Diabetic patients of insomnia with or without anti-diabetic drugs
    • Diabetic patients of insomnia with or without Hypomagnesaemia
    • Diabetic patients of insomnia with or without Hypokalemia

Exclusion Criteria:

  • Individuals with the following conditions will not be included as participants, patients of diabetes mellitus with insomnia with

    • Psychiatry reasons
    • Any hormonal treatment
    • CVD/ Other metabolic co-morbidities
    • History of acute liver injury (e.g., hepatitis) or severe cirrhosis
    • Renal diseases (renal stones, renal failure, dialysis)
    • Diabetic nephropathy
    • Pregnancy
    • Breast-feeding
    • Drug induced insomnia
    • Sleep disorders
    • Sleep-related movement disorders (restless leg syndrome)
    • Sleep-related respiratory disorders (sleep apnea)
    • Alcohol consumption
    • Cardiac respiratory disorders
    • Painful condition (apathy)
    • History of chronic liver disease
    • History of CKD
    • Participation in a study of an investigational medication or nutritional supplements/ medication within the past 90 days

Sites / Locations

  • Akhuwat Health ServicesRecruiting
  • The University of LahoreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

PLACEBO group

Magnesium group

Potassium group

Magnesium + Potassium group

Arm Description

Placebo treatment: starch tablets (250 mg)

Magnesium group: Magnesium gluconate (250 mg)

Potassium group: Potassium chloride (250 mg)

Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)

Outcomes

Primary Outcome Measures

Effects of magnesium and/ or potassium supplementation on insomnia severity patients with diabetes mellitus
Insomnia Severity Index (ISI) will be used to assess and categorize the insomnia among patients with diabetes mellitus, before and after the intervention
Effects of magnesium and/ or potassium on insulin resistance among insomnia patients with diabetes mellitus
Homeostatic model assessment for insulin resistance (HOMA-IR) will be used to measure the insulin resistance before and after the Mg, K supplementation among insomniac patients with diabetes mellitus. Insulin will be measured through ELISA technique.
Effects of magnesium and/ or potassium on sleep hormones (melatonin, cortisol) among insomniac patients with diabetes mellitus.
Sleep hormones (melatonin, cortisol) will be measured before and after the intervention, through ELISA technique, among insomniac patients with diabetes mellitus.
Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus
Serum magnesium and/ potassium (in blood) will be measured through chemistry analyzer, before and after the Mg, K supplementation among insomniac patients with diabetes mellitus

Secondary Outcome Measures

Effect of magnesium and/ or potassium on quality of life (QOL) among insomnia patients with diabetes mellitus
WHOQOL-BREF will be used to measure quality of life before and after the Mg, K supplementation, among insomniac patients with diabetes mellitus.
Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus
Gender and age based responses of Mg, K supplementation will be compared among insomniac patients with diabetes mellitus

Full Information

First Posted
November 9, 2020
Last Updated
November 17, 2020
Sponsor
University of Lahore
search

1. Study Identification

Unique Protocol Identification Number
NCT04642313
Brief Title
Comparison of Mg Vs. K Supplementation on Insomnia in Diabetics
Official Title
Comparison of Magnesium Versus Potassium and Their Combined Effect on Insomnia, Sleep Hormones, Insulin Resistance and Quality of Life Among Patients With Diabetes Mellitus".
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 26, 2020 (Actual)
Primary Completion Date
April 26, 2021 (Anticipated)
Study Completion Date
April 26, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Lahore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Insomnia is increasing alarmingly among the population. Micronutrient fluctuations have been shown to effect insulin secretion, period of circadian cycle and quality of sleep in all ages. This study is aimed to identify the impact of magnesium and potassium supplementation on insomnia severity and duration, and insulin resistance, quality of life, sleep hormones, serum magnesium and potassium levels. Moreover, the study will help to find out the link between insomnia and micronutrients among patients of diabetes mellitus so that the burden of the disease in the society could be reduced.
Detailed Description
Sleep is the essential component to maintain good health of an individual. Insomnia is defined as a condition that affects an individual by inability to get sufficient quality sleep or problem in maintaining sleep that is important for healthy functioning, performance and well being. Insomnia can exist in healthy individual or comorbidly with other medical diseases. Latest researches indicate that intolerance of glucose in the body, resistance to insulin hormone, decreased acute response of insulin to glucose and increased chances of having type 2 diabetes are reasons for reduced or interrupted sleep. Several electrolytes and minerals influence the sleep cycle. Magnesium is important in regulation of central nervous system excitability, through ion channel conductivity. Magnesium is a muscle relaxant and inducer of the deeper sleep. Hypomagnesemia is a common feature in patients with type 2 diabetes. Although diabetes can induce hypomagnesemia, magnesium deficiency has also been proposed as a risk factor for type 2 diabetes. Magnesium supplementation improves sleep efficiency, sleep time and sleep onset latency, early morning awakening, and insomnia objective measures such as the concentration of serum renin, melatonin, and serum cortisol, in older adults. High ambient potassium levels have been shown to shorten the period of circadian rhythms in a variety of organisms. Little is known about the effects of dietary mineral nutrients on human sleep quality. Potassium depletion has been shown to cause glucose intolerance, which is associated with impaired insulin secretion . Recently, there has been growing evidence from both animal and human studies indicating that high sodium and low potassium intakes are associated with a high risk of insulin resistance or diabetes. The Study is aimed to: To compare the effect of magnesium and/ or potassium on insomnia patients with diabetes mellitus To compare the gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus To compare the effect of magnesium and/ or potassium on insulin resistance among insomnia patients with diabetes mellitus To compare the effect of magnesium and/ or potassium on sleep hormones among insomnia patients with diabetes mellitus To compare the effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus To compare the effect of magnesium and/ or potassium on quality of life (QOL) among insomnia patients with diabetes mellitus MATERIAL AND METHODS Study Design: Randomized Controlled Trial (single blind) Settings: Study will be conducted at 1. Akhuwat Health Services, Lahore Duration of Study: 18 months (after the approval of synopsis) Sample Size: is 280 and with expected 20% drop out: 320 Sampling Technique: Non probability purposive sampling Inclusion Criteria: Patients of diabetes mellitus with insomnia Adult diabetic patients aged between 19 to 65 years Patients of both genders Diabetic patients of insomnia with or without antidiabetic drugs

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Focus of Study is on Insomnia Among Diabetic Patients
Keywords
Insomnia, Diabetes Mellitus, Magnesium, Potassium, Melatonin, Cortisol, Insulin resistance, Quality of Life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be divided into 4 groups and will receive 4 different treatments at same time
Masking
Participant
Masking Description
It will be single blind study, Participants will not be aware of the treatment group, they are receiving
Allocation
Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PLACEBO group
Arm Type
Placebo Comparator
Arm Description
Placebo treatment: starch tablets (250 mg)
Arm Title
Magnesium group
Arm Type
Experimental
Arm Description
Magnesium group: Magnesium gluconate (250 mg)
Arm Title
Potassium group
Arm Type
Experimental
Arm Description
Potassium group: Potassium chloride (250 mg)
Arm Title
Magnesium + Potassium group
Arm Type
Experimental
Arm Description
Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
Intervention Type
Other
Intervention Name(s)
Magnesium and/ or Potassium
Intervention Description
Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
Primary Outcome Measure Information:
Title
Effects of magnesium and/ or potassium supplementation on insomnia severity patients with diabetes mellitus
Description
Insomnia Severity Index (ISI) will be used to assess and categorize the insomnia among patients with diabetes mellitus, before and after the intervention
Time Frame
60 days
Title
Effects of magnesium and/ or potassium on insulin resistance among insomnia patients with diabetes mellitus
Description
Homeostatic model assessment for insulin resistance (HOMA-IR) will be used to measure the insulin resistance before and after the Mg, K supplementation among insomniac patients with diabetes mellitus. Insulin will be measured through ELISA technique.
Time Frame
60 days
Title
Effects of magnesium and/ or potassium on sleep hormones (melatonin, cortisol) among insomniac patients with diabetes mellitus.
Description
Sleep hormones (melatonin, cortisol) will be measured before and after the intervention, through ELISA technique, among insomniac patients with diabetes mellitus.
Time Frame
60 days
Title
Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus
Description
Serum magnesium and/ potassium (in blood) will be measured through chemistry analyzer, before and after the Mg, K supplementation among insomniac patients with diabetes mellitus
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Effect of magnesium and/ or potassium on quality of life (QOL) among insomnia patients with diabetes mellitus
Description
WHOQOL-BREF will be used to measure quality of life before and after the Mg, K supplementation, among insomniac patients with diabetes mellitus.
Time Frame
60 days
Title
Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus
Description
Gender and age based responses of Mg, K supplementation will be compared among insomniac patients with diabetes mellitus
Time Frame
60 days
Other Pre-specified Outcome Measures:
Title
Effect of magnesium and/ or potassium on quality liver function tests (LFTs) among insomnia patients with diabetes mellitus
Description
Liver function tests (ALT, AST) will measured before and after the Mg, K supplementation among insomniac patients with diabetes mellitus
Time Frame
60 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Patients of diabetes mellitus with insomnia Adult diabetic patients aged between 19 to 65 years Patients of both genders Diabetic patients of insomnia with or without anti-diabetic drugs Diabetic patients of insomnia with or without Hypomagnesaemia Diabetic patients of insomnia with or without Hypokalemia Exclusion Criteria: Individuals with the following conditions will not be included as participants, patients of diabetes mellitus with insomnia with Psychiatry reasons Any hormonal treatment CVD/ Other metabolic co-morbidities History of acute liver injury (e.g., hepatitis) or severe cirrhosis Renal diseases (renal stones, renal failure, dialysis) Diabetic nephropathy Pregnancy Breast-feeding Drug induced insomnia Sleep disorders Sleep-related movement disorders (restless leg syndrome) Sleep-related respiratory disorders (sleep apnea) Alcohol consumption Cardiac respiratory disorders Painful condition (apathy) History of chronic liver disease History of CKD Participation in a study of an investigational medication or nutritional supplements/ medication within the past 90 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sidra Khalid
Phone
0923347498338
Email
sidrakhalid.uaf@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Shahid Bashir, PhD
Phone
092423200865
Ext
5967
Email
shahid.bashir@rsmi.uol.edu.pk
Facility Information:
Facility Name
Akhuwat Health Services
City
Lahore
State/Province
Punjab
ZIP/Postal Code
54000
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Waseem Abbas, FCPS
Phone
0923314527672
Email
wasimhashmi14@gmail.com
Facility Name
The University of Lahore
City
Lahore
State/Province
Punjab
ZIP/Postal Code
54000
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shahid Bashir, PhD
Phone
0924232300865
Ext
5967
Email
shahid.bashir@rsmi.uol.edu.pk

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Patients data will be kept confidential and their identity will not be revealed

Learn more about this trial

Comparison of Mg Vs. K Supplementation on Insomnia in Diabetics

We'll reach out to this number within 24 hrs